New system finds and targets vulnerabilities in lung cancer cells

October 2, 2017, NYU Langone Health
Lung CA seen on CXR. Credit: James Heilman, MD/Wikipedia

Genetic changes that help lung cancer thrive also make it vulnerable to a promising experimental drug, according to a study led by researchers from Perlmutter Cancer at NYU Langone Health, and published online October 2 in Nature Medicine.

Specifically, the study found that mutations in the DNA code for the gene KEAP1 help lung adenocarcinoma counter a process called oxidative stress, in which molecules known as reactive oxygen species (ROS) are created as a side effect of "burning" fuel to make energy. Cancer cells need extra fuel to support abnormal growth, produce more ROS, and depend more for survival on naturally occurring antioxidants that keep ROS from damaging cell parts.

The new study confirmed that mutations that weaken KEAP1 function lead to greater production of antioxidants. It also found that KEAP1 mutations create vulnerability in when combined with changes in the gene KRAS, which cause cancer cells to multiply aggressively.

The vulnerability found by the new study reflects the ability of lung adenocarcinoma cells to use extra fuel sources in support of . Along with the blood sugar that most cells use, cancer cells also break down a compound called glutamate to make energy, say the study authors. At the same time, such cells also expel glutamate as part of a process that supports the building of antioxidants. Importantly, cancer cells cannot both break down for energy, and expel, the same molecule of glutamate.

Recognizing this "competition" for glutamate as a weakness, the research team showed that the experimental drug CB-389 stopped tumor growth in mice with KRAS and KEAP1 mutations by cutting off the glutamate supply. Because adenocarcinoma cells with KEAP1 mutations used up so much glutamate to enable antioxidant production, they did not have enough to fuel aggressive, KRAS-driven growth. Consequently, they starved.

"Our study results suggest that a drug currently in clinical trials may be more effective against cancers with combined KRAS and KEAP1 mutations, which represents perhaps ten percent of patients diagnosed each year with lung adenocarcinoma or 9,000 patients per year," says corresponding study author Thales Papagiannakopoulos, PhD, assistant professor in the Department of Pathology at NYU School of Medicine.

First of Many Vulnerabilities

To make their discovery, the research team used the revolutionary gene editing system called CRISPR-Cas9. Using a virus to introduce this system into mouse lung cells, the investigators made their desired genetic changes in months instead of the years needed for conventional gene targeting. The team then disabled the KEAP1 gene in that already had KRAS mutations, and metabolic tests confirmed the glutamate supply vulnerability this process created. Drug screens subsequently revealed that the Phase I clinical trial drug, CB-839, might be especially useful against cells with this combination of mutations.

Moving forward, Papagiannakopoulos says he has approached Calithera, the company developing CB-389, about the possibility of testing whether the drug is more effective in patients with KRAS and KEAP1 mutations. Beyond lung cancer, a second study published this week by the same team in the journal eLife found that KEAP-1 mutations might also make glutaminase inhibitors such as CB-389 more effective against other cancers, including melanoma, bone cancer, kidney cancer, urinary tract cancer, and colon cancer.

KRAS and KEAP1 represent just two on the team's list of the 18 most commonly mutated genes in lung adenocarcinoma. The researchers plan to work down the list, confirming the contribution of in each gene to cell survival, revealing related metabolic dependencies, and screening for drugs that may leverage them.

About 222,500 new cases of are diagnosed each year, according to the American Cancer Society. About 40 percent of cancers are adenocarcinomas, which start in cells that would normally secrete mucus.

Explore further: Editing genes one by one throughout colorectal cancer cell genome uncovers new drug target

More information: Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis, Nature Medicine (2017). nature.com/articles/doi:10.1038/nm.4407

Related Stories

Editing genes one by one throughout colorectal cancer cell genome uncovers new drug target

September 27, 2017
Cancers driven by mutations in the KRAS gene are among the most deadly. For decades, researchers have tried unsuccessfully to directly target mutant KRAS proteins as a means to treat tumors. Instead of targeting mutant KRAS ...

Researchers develop new strategy to target KRAS mutant cancer

September 14, 2017
Although KRAS is one of the major oncogenes associated with aggressive cancers, drugs designed to block KRAS function have not been able to halt cancer progression in a clinical setting. Until now, KRAS has remained infamously ...

Researchers identify possible new target in fight against lung cancer

September 12, 2017
Researchers at Boston University School of Medicine (BUSM) have identified a molecule called miR-124 in non-small cell lung cancer cells that plays a regulatory role in the cancer cells' fate—determining whether or not ...

Mutations unveiled that predispose lung cancers to refractory histologic transformation

June 7, 2017
Cancer pedigree analysis reveals the mutations in RB1 and TP53 genes play a key role in treatment-resistant, cancer cell-type transformation during EGFR inhibitor therapy for lung cancers.

Researchers identify mechanism of oncogene action in lung cancer

January 19, 2017
Researchers at Mayo Clinic have identified a genetic promoter of cancer that drives a major form of lung cancer. In a new paper published this week in Cancer Cell, Mayo Clinic researchers provide genetic evidence that Ect2 ...

New subsets of lung cancer with KRAS gene mutations identified

April 20, 2015
Mutations of the KRAS gene are commonly known to lead to cancer. However, deeper understanding of exactly how they do this continues to be explored by cancer researchers.

Recommended for you

Eating foods with low nutritional quality ratings linked to cancer risk in large European cohort

September 18, 2018
The consumption of foods with higher scores on the British Food Standards Agency nutrient profiling system (FSAm-NPS), reflecting a lower nutritional quality, is associated with an increased risk of developing cancer, according ...

CRISPR screen reveals new targets in more than half of all squamous cell carcinomas

September 18, 2018
A little p63 goes a long way in embryonic development—and flaws in p63 can result in birth defects like cleft palette, fused fingers or even missing limbs. But once this early work is done, p63 goes silent, sitting quietly ...

Could the zika virus fight the brain cancer that killed john McCain?

September 18, 2018
(HealthDay)—Preliminary research in mice suggests that the Zika virus might be turned from foe into friend—enlisted to curb deadly glioblastoma brain tumors.

Enlarged genotype-phenotype correlation for a three-base pair deletion in neurofibromatosis type 1

September 18, 2018
International collaborative research led by Ludwine Messiaen, Ph.D., shows that while a three-base pair, in-frame deletion called p.Met992del in the NF1 gene has a mild phenotype for people with the genetic disorder neurofibromatosis ...

Your teen is underestimating the health risks of vaping

September 17, 2018
Teens today are more reluctant to smoke cigarettes than their counterparts nearly three decades ago, according to a study released this summer. But parents should hold their collective sigh of relief. The study, carried out ...

Artificial intelligence can determine lung cancer type

September 17, 2018
A new computer program can analyze images of patients' lung tumors, specify cancer types, and even identify altered genes driving abnormal cell growth, a new study shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.